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Introduction {#sec1}
============

During embryogenesis, morphogen gradients control patterning as well as growth of tissues and organs ([@bib14], [@bib56], [@bib60]). Some morphogens are growth factors expressed from a restricted group of cells in developing tissues, from where they are secreted and form concentration gradients. In some cases, they endow cells with positional information by activating different target genes at different morphogen concentration thresholds. The shape of the gradient patterns the tissue.

One remarkable feature of some morphogen gradients is their ability to adapt spatially to tissues of different sizes: the gradient shape is invariant and scales to keep the morphological patterns proportional, independent of organ size. Not all morphogen gradients scale (see for example the Hedgehog gradient in the wing \[[@bib58]\]) and, as already discussed by Wolpert, how gradients could possibly scale is not a trivial issue ([@bib60]). But morphogenetic gradient scaling has indeed been shown to regulate different aspects of scale invariant patterning during animal development in planarians, insects, and vertebrates ([@bib4], [@bib11], [@bib25], [@bib51], [@bib53], [@bib58]). Importantly, it has been proposed that gradient scaling can also control tissue growth. In insects, cells sense the relative fold increase in bone morphogenetic protein (BMP) signaling over time, so that cells divide when a signaling threshold is met ([@bib58], [@bib59]). In this context, gradient scaling can mediate the increase in the cellular signaling levels over time, which is necessary for growth.

The mechanisms underlying gradient scaling are not yet understood. Different studies have proposed that gradient scaling can be achieved by morphogen advection-dilution or by more complex processes such as two opposing gradients, shuttling, the interplay between a source and a sink, or by means of an expander-repression mechanism ([@bib6], [@bib10], [@bib36], [@bib49], [@bib63]). In particular, the expansion-repression mechanism involves an expander molecule that relays information about the size of the tissue into the morphogen gradient, allowing for its scaling. In this model, the expander transcription is repressed by the morphogen and is thereby restricted to the edge of the gradient ([@bib10]). From there, the expander diffuses throughout the target tissue and promotes the expansion of the gradient by regulating morphogen degradation and/or diffusion. The fact that the expander is expressed at the edge of the gradient and the tissue, encodes the necessary information to compare the length of the gradient with the size of the tissue: expander expression increases if the tissue is bigger than the gradient. A candidate molecule for an expander has been proposed in insects, Pentagone ([@bib57]). Pentagone is indeed expressed at the edge of a BMP gradient, controls degradation of the ligand, and is essential for the scaling of the gradient ([@bib12], [@bib20], [@bib59]).

In vertebrates, during embryonic dorso-ventral axis specification, TGFβ family ligands are also distributed as gradients of concentration. In particular, in *Xenopus* and zebrafish, both BMP and Nodal form gradients which mediate patterning and scale, adapting to embryo size ([@bib4], [@bib11], [@bib25], [@bib46]). Instead of looking at embryos of different sizes, here we study how a gradient expands and scales in an organ as it grows. In particular, we investigate BMP signaling in the zebrafish pectoral fin during its proliferation phase in the embryo ([@bib41], [@bib61]). The pectoral fin is the homolog of the tetrapod forelimbs, being initially comprised by a mesenchymal bud and surrounding ectodermal cells. Later, while the fin extends its proximal-distal axis, it defines two regions: the endoskeletal disc proximally and the apical fold distally ([@bib19], [@bib38]). Despite extensive knowledge about the contribution of signaling molecules necessary to establish these patterns, the mechanisms controlling fin growth and its coordination with patterning are not understood ([@bib38], [@bib61]).

Here we propose that BMP signaling gradients regulate pectoral fin growth by means of gradient scaling, mediated by an expansion-repression mechanism. In the fin, we found that two BMP signaling gradients are established and scale in two dimensions with the fin's size. Importantly, we show that gradient scaling is coupled to the relative increase in BMP signaling over time, which could underlie the regulation of cell division and organ size. Furthermore, we identify a vertebrate expander molecule, Smoc1, which participates in a regulatory feedback loop with the BMP gradients. BMP gradient scaling in the pectoral fin is fine-tuned through an expansion-repression mechanism, allowing for gradient scaling during fin growth.

Results {#sec2}
=======

Two BMP Signaling Gradients during Pectoral Fin Growth {#sec2.1}
------------------------------------------------------

In zebrafish, previous studies have shown that BMP signaling regulates embryonic fin growth ([@bib41]; [Figures S1](#mmc1){ref-type="supplementary-material"}A--S1I). To study the dynamics of BMP signaling during this process, we imaged transgenic fish carrying reporter constructs based on a BMP responsive element (BRE; [Figure 1](#fig1){ref-type="fig"}; [Video S1](#mmc2){ref-type="supplementary-material"}). These BRE reporters have been previously used as live sensors of BMP signaling in zebrafish, given that GFP is expressed under the control of Smad1/5/8 enhancers from the mouse Id1 promoter ([@bib13], [@bib30], [@bib31]).Figure 1BMP Signaling Gradients in the Pectoral Fin(A--C) Fin of double transgenic BRE:GFP (green) and Histone2b-mCherry (red), at 60 hpf. The BRE reporter expresses GFP under the control of Smad1/5/8 enhancers from the mouse Id1 promoter ([@bib13], [@bib31]). Dashed line, fin boundaries. Anterior, left; distal, down.(B) Region of interest (ROI, blue; with ROI midline) where gradients are deployed: endoskeletal disc, abutting the fin fold. Cartoon indicates fin axes and endoskeletal disc (ed).(D) BRE:GFP gradient along the straightened ROI (blue; anterior left) from (B). Orange lines indicate position $s = 0$, corresponding to intensity maxima. Length $L$ (black line), distance between each peak signal and the ROI midpoint (dashed line).Scale bars: 50 μm (A--C), 20 μm (D).(E) BRE:GFP intensity profile along the ROI midline from (B)--(D), at 60 hpf. Arrowheads, intensity maxima. Intensity corresponds to signal average orthogonal to midline.(F and G) Anterior (F) and posterior (G) intensity profiles from (E) versus position $s$, with respective decay lengths (λ, slope), ± SEM. Here $s = 0$, position of peak signal as indicated in (D)--(E). Note that the gradient profile corresponds to different levels of signaling per cell and the observed gradient is not due to different cell density or different number of signaling cells (see [Figures S2](#mmc1){ref-type="supplementary-material"}K--S2M). Also, the gradient does not reflect different durations of signaling or long perdurance of GFP in the BRE reporter, since Phospho-Smad1/5/9 immunostainings show similar graded distributions ([Figures S1](#mmc1){ref-type="supplementary-material"}J--S1L). Black lines, exponential fits with respective goodness of fit (R^2^). BRE:GFP transgene used: BRE:eGFP ([@bib31]).See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Video S1. BRE:GFP Gradients in the Pectoral Fin. Related to Figure 1This movie shows a pectoral fin expressing BRE:GFP (from [@bib31]) from 33 to 86 hpf (time stamp), with acquisition every 10min, by SPIM. Square represents area considered for $C_{0}$ measurements. Scale bar, 50μm.

During pectoral fin development, we found that BMP signaling forms two spatial concentration gradients that decay along the proximo-distal axis, in the anterior and posterior sides of the endoskeletal disc ([Figures 1](#fig1){ref-type="fig"}A--1E). This signaling pattern was confirmed by anti-Phospho-Smad1/5/9 immunostainings ([Figures S1](#mmc1){ref-type="supplementary-material"}J--S1L; [@bib13]). Consistent with the formation of proximo-distal signaling gradients, the BMP2a ligand has been shown to be expressed at the proximal base of the fin ([@bib34], [@bib40]) and the BmpR1b receptor is present throughout the endoskeletal disc ([Figures S1](#mmc1){ref-type="supplementary-material"}M--S1O). In the center of the endoskeletal disc, lower levels of signaling correlate with the expression of Noggin, a BMP inhibitor that binds the ligand, thereby competing with the receptor ([@bib18], [@bib62]). Therefore, in addition to the proximo-distal decays, the signaling gradients also decay toward the center of the endoskeletal disc ([Figures S1](#mmc1){ref-type="supplementary-material"}P--S1S).

The fin primordium is a 3D object with dorso-ventral (DV), antero-posterior (AP), and proximo-distal (PD) axes. Since the fin endoskeletal disc is thin along the DV axis ([Figure S2](#mmc1){ref-type="supplementary-material"}A), we projected the BRE signal to consider only the PD/AP plane. In this surface, the BRE signal $C\left( s \right)$ fit exponential curves $C\left( s \right) = C_{0}e^{{- s}/\lambda}$, with $s$, the position along the gradient; $\lambda$, its length scale; and $C_{0}$, its amplitude, i.e., the maximal concentration at the proximal side of the fin. An exponential profile captures the shape of the gradient, whether we considered the distance $s$ along the gradient (ROI in [Figures 1](#fig1){ref-type="fig"}B, 1D, 1F, and 1G) or the position ($x$, $y$) along the PD and AP axes ([Figures S2](#mmc1){ref-type="supplementary-material"}D--S2J; see [STAR Methods](#sec4){ref-type="sec"} and [Supplemental Methods](#mmc1){ref-type="supplementary-material"} for Theoretical Framework).

The anterior and posterior gradients have approximately the same length scale of about 5 cell diameters (around 28 μm) at 60 h post-fertilization (hpf; [Figures 1](#fig1){ref-type="fig"}F and 1G). The amplitude of the anterior gradient is smaller than that of the posterior ([Figures 1](#fig1){ref-type="fig"}E, [S2](#mmc1){ref-type="supplementary-material"}B, and S2C). This is consistent with previous reports, showing that BMP2a expression at the base of the fin is stronger in the posterior side ([@bib34], [@bib40]).

The two gradients can be observed from 48 to 78 hpf, a larval period in which the pectoral fin grows actively, doubling its proximo-distal length ([Figures 2](#fig2){ref-type="fig"}A--2F and 2M). Before 48 hpf, the gradients are too faint to quantify reliably and after 78 hpf, the profile does not fit an exponential curve, due to high levels of expression in single mesenchymal cells ([Figures S1](#mmc1){ref-type="supplementary-material"}T and S1U).Figure 2Pectoral Fin Growth(A--F) Scanning electron micrographs of larvae (A--C) and fins (D--F) at different times. Cartoon indicates fin orientation.(G--I) DAPI (blue) and Phospho-histoneH3 immunostainings (red) at different times.(J--L) Overlay of fins expressing zGeminin. LUT shows number of overlaid zGeminin^+^ nuclei per pixel. Dashed line, fin boundary. Distal, down; anterior, left.(M) PD and AP fin lengths from SEM images.(N) Number of phospho-histoneH3 cells per 10,000 μm^2^ at different times. Line, exponential fit with goodness of fit (R^2^).(O) Log-log plot of AP versus PD lengths to determine anisotropy $\varepsilon$ (slope value) ± SEM. Line, power-law fit with goodness of fit (R^2^).Black dots, average from developmental time bins. Mean ± SEM are shown in all graphs. n represents total number of fins analyzed/overlaid. Scale bars, 100 μm (A--C), 50 μm (D--L).

Fin Growth Is Homogeneous and Anisotropic {#sec2.2}
-----------------------------------------

To study the BMP gradients as the fin grows, we first characterized fin growth by scanning electron microscopy ([Figures 2](#fig2){ref-type="fig"}A--2F and 2M) and cell proliferation, by imaging Fucci live sensors (S/G2/M marker) ([@bib52]) as well as performing phospho-histone H3 immunostainings (mitosis marker) ([@bib21]) ([Figures 2](#fig2){ref-type="fig"}G--2L and 2N). We observed that, from 48 to 95 hpf, the proliferation rate decays exponentially, with growth stopping around 78 hpf ([Figure 2](#fig2){ref-type="fig"}N).

The even distribution of cells in S/G2/M throughout the fin primordium ([Figures 2](#fig2){ref-type="fig"}J--2L) indicates that proliferation is approximately homogeneous until 72 hpf; growth ceases around this time ([Figure 2](#fig2){ref-type="fig"}N), when some heterogeneity can be observed ([Figure 2](#fig2){ref-type="fig"}L), as previously reported ([@bib15], [@bib19]). Dorso-ventral fin growth is negligible ([Figure S2](#mmc1){ref-type="supplementary-material"}A), and growth is anisotropic along the two other axes, with a larger PD growth rate: $\varepsilon = \left( {g_{AP}/g_{PD}} \right) = 0.65 \pm \ 0.024\ $([Figures 2](#fig2){ref-type="fig"}M and 2O). While fin proliferation is approximately uniform, BMP signaling is graded, indicating that the growth rate does not correlate with the levels of signaling. Instead, previous reports have shown that the dynamics of BMP signaling can control cell proliferation ([@bib58], [@bib59]). For this reason, we studied next the dynamics of signaling as the fin develops.

The BMP Gradients Scale with the Size of the Fin {#sec2.3}
------------------------------------------------

As the fin grows, the decay lengths of both anterior and posterior BRE gradients expand. The anterior and posterior decay lengths are approximately the same and both are proportional to tissue length $L$ (half-length along the ROI midline): $\varphi_{A} = \left( {\lambda_{A}/L} \right) = 0.31 \pm 0.04$ and $\varphi_{P} = \left( {\lambda_{P}/L} \right) = 0.35 \pm 0.05$ ([Figures 3](#fig3){ref-type="fig"}A--3D and [S2](#mmc1){ref-type="supplementary-material"}D--S2J). We observed similar gradient scaling with fin size with anti-Phospho-Smad1/5/9 immunostainings ([Figures S4](#mmc1){ref-type="supplementary-material"}I, S4K, S4L). We also studied the scaling of the gradient without committing to exponential fits, using an alternative method based on analyzing the collapse of the gradients into a single curve profile as the tissue grows ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4D; [@bib58]).Figure 3Scaling of BMP Signaling Gradients(A and B) BRE:GFP gradients at different times as a function of the distance to intensity maxima ($s = 0$, ROI midline). Bold lines, exponential fits.(C and D) Decay length versus ROI half-length $\left( L \right)$ of BRE:GFP gradients. Blue dots, individual data; black dots, average from length bins ± SEM. Slope $\left( \varphi \right)$ values ± SEM are shown. Lines, linear fits with goodness of fit: $\varphi_{A}$$R^{2}$ = 0.58; $\varphi_{P}$$R^{2}$ = 0.55.(E and F) Average dynamics of gradient amplitude ($C_{0}$; SPIM imaging). Orange, growth phase (48--78 hpf).(G) Log-log plot of normalized average amplitude ${{C_{0}\left( t \right)}/C_{0}}\left( {45\ \text{hpf}} \right)$ versus normalized endoskeletal disc PD length ${{L\left( t \right)}/{L\ }}\left( {45\ \text{hpf}} \right)$, to estimate $q$ (slope value), with SEM. Power-law fit with goodness of fit (R^2^).Shadowing corresponds to SEM per time point (E, F) or length (G). n represents number of fins analyzed. BRE:GFP transgene used: BRE:eGFP ([@bib31]) (A--D); BRE-AAVmlp:eGFP ([@bib13]) (E--G). See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Because of homogeneous growth ([Figures 2](#fig2){ref-type="fig"}J--2L), the relative position of cells does not change as the tissue grows ($r_{\text{cell}}\left( t \right) = {{x\left( t \right)}/{L\left( t \right)}}$ is constant). In addition, due to scaling ([Figures 3](#fig3){ref-type="fig"}C and 3D), the normalized signaling level $C{\left( {r_{\text{cell}},t} \right)/{C_{0}\left( t \right)}}$ in any particular cell in the tissue does not change over time ([@bib3], [@bib58]). Since $C{\left( {r_{\text{cell}},t} \right)/{C_{0}\left( t \right)}}$ for each cell is constant, then the signaling level $C\left( {r_{\text{cell}},t} \right)$ of each cell increases proportionally to the amplitude $C_{0}\left( t \right)$ of the gradient, i.e., when the amplitude of the gradient doubles in a particular cell, it doubles in all fin cells. Therefore, the dynamics of $C_{0}\left( t \right)$ at the source boundary reflect the dynamics of BMP signaling in every other cell in the tissue---this prompted us to study $C_{0}\left( t \right)$ in detail during pectoral fin growth. The amplitude $C_{0}$ increases as the fin grows, consistent with a power-law relationship $C_{0} = L^{q}$, given the endoskeletal disc PD length$\ L$, with $q = 0.92\text{~±~}0.01$ ([Figures 3](#fig3){ref-type="fig"}E--3G). A value of the exponent close to one means effectively that the relationship between $C_{0}$ and $L$ can be captured by a quasi-linear dependence. If gradient scaling fuels fin growth, what is the machinery of scaling?

Expander Molecule in Zebrafish: Smoc1 {#sec2.4}
-------------------------------------

It has been proposed that secreted molecules can function as "expanders" of the gradient by acting on morphogen diffusion and/or degradation ([@bib10]). These expanders would act as BMP agonists, extending the gradient. Beyond mere expansion, a feedback loop, where BMP signaling represses expander expression, can achieve scaling by keeping the decay length proportional to tissue length ([@bib10]). This implies that the expander is expressed only at the edge of the gradient, i.e., at low levels of BMP signaling. Being restricted to the edge of the tissue, the expander expands the gradient when the length of the gradient is shorter than the tissue itself: the expander adjusts (i.e., scales) the gradient to the tissue.

A *Drosophila* secreted molecule, Pentagone, fulfils these features and is essential to scale BMP2/4 gradients in the wing and eye ([@bib57], [@bib59]). In heterologous overexpression experiments, Pentagone can cause BMP-like defects during dorso-ventral patterning in fish ([@bib57]). In vertebrates, Sparc related modular calcium binding 1 (Smoc1) is the ortholog of Pentagone, and *Xenopus* Smoc1 has been shown to interfere with BMP signaling ([@bib55]). Furthermore, Smoc1 is associated with Waardenburg anophthalmia syndrome in humans and mutant mice show defects in their limbs and eyes, phenotypes associated with BMP defects ([@bib1], [@bib42]).

To study whether Smoc1 plays a role in BMP scaling in the fin, we analyzed the pattern of expression of Smoc1, as well as generated morphants and a CRISPR mutant. Smoc1 is expressed as a gradient, with maximal concentration at the distal region of the fin, between the two BMP gradients, i.e., where BMP signaling levels are lowest ([Figures 4](#fig4){ref-type="fig"}A--4C, 4H, and [S3](#mmc1){ref-type="supplementary-material"}A--S3K). This is consistent with the idea that BMP signaling itself represses Smoc1. Indeed, blocking BMP signaling by conditional expression of a dominant-negative version of the BMP receptor-1a ([@bib44]) upregulates Smoc1 ([Figures 4](#fig4){ref-type="fig"}D--4G and 4I), confirming the negative feedback loop. While Smoc1 expands the BMP gradient (Smoc1 agonizes BMP, see below), this negative feedback (BMP antagonizes Smoc1) closes a loop of regulation to achieve scaling, as previously proposed in invertebrates ([@bib10], [@bib57]).Figure 4Smoc1 Is Repressed by BMP Signaling(A--C) BRE:GFP signal (green) and Smoc1 immunostaining (red) in the fin, at 48 hpf.(D--G) Smoc1 expression pattern at 2 h post-heat-shock induction (hpHS) of a dominant-negative BMP receptor transgene (dnBmpr-GFP^+^) or in sibling controls (for heat-shock conditions, see [STAR Methods](#sec4){ref-type="sec"}), at 48 hpf. Inset, GFP immunostaining to monitor expression of transgene.(H) Average intensities of normalized Smoc1 immunostainings and BRE:GFP signal versus relative position (ROI midline), at 48 hpf. Intensities were normalized to respective maxima.(I) Average intensity of normalized Smoc1 immunostainings versus relative position (ROI midline) in dnBmpr-GFP^+^ transgenics and siblings control. Smoc1 intensity in dnBmpr-GFP^+^ was normalized to the control maxima. Shadowing corresponds to SEM per relative position (H, I).Scale bars, 50 μm. n represents number of fins analyzed. Anterior, left; distal, down. BRE:GFP transgene used: BRE:eGFP ([@bib31]) (A--C, H). See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Smoc1 Scales the Anterior Gradient and Controls Fin Growth {#sec2.5}
----------------------------------------------------------

Is Smoc1 implicated in the scaling of the BMP gradient in the fin? To address this, we generated a Smoc1 CRISPR mutant that carries a stop codon in the 5′ region of the coding sequence (*Smoc1*^*ug104*^; [Figures 5](#fig5){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}M--S3U; [STAR Methods](#sec4){ref-type="sec"}). This mutant recapitulates a previously reported microphthalmia phenotype caused by a validated splicing morpholino ([Figures S3](#mmc1){ref-type="supplementary-material"}L and S3O--S3U; [@bib1]). Interestingly, *Smoc1* homozygous mutants fail to scale the anterior BRE gradient: the decay length does not expand as the fin length grows ([Figures 5](#fig5){ref-type="fig"}C, 5D, 5F, and [S4](#mmc1){ref-type="supplementary-material"}W). Similar results were obtained with Phospho-Smad 1/5/9 immunostainings ([Figures S4](#mmc1){ref-type="supplementary-material"}J, S4M, and S4N) and by performing collapse analysis ([Figures 5](#fig5){ref-type="fig"}L and [S4](#mmc1){ref-type="supplementary-material"}E--S4H).Figure 5Smoc1 Mutants Scaling Phenotype(A) *smoc1* genomic structure. Exon colors match the protein domains they encode: SP, signal peptide; FS, follistatin-like domain; Thy, thyroglobulin-like domain; EC, extracellular domain. Target sequence of the *Smoc1*^*ug104*^ CRISPR mutant is located in exon 4; mutant sequence of *Smoc1*^*ug104*^, highlighted in magenta. *Smoc1*^*ug104*^ results in a truncated protein, which lacks the first Thyroglobulin domain and other downstream features. The position of the splicing morpholino and Smoc1 antibody epitope region are indicated.(B and C) BRE:GFP gradients in *Smoc1* homozygote mutants (C) and heterozygote controls (B) displayed as straightened ROI, as in [Figure 1](#fig1){ref-type="fig"}D (anterior, left).(D and E) Decay length versus ROI half-length $\left( L \right)$ of BRE:GFP gradients in *Smoc1*^*−/−*^ mutants (black) and wild-type controls (green, from [Figures 3](#fig3){ref-type="fig"}C and 3D). Dots, average from length bins ± SEM (for individual data points, see [Figures S4](#mmc1){ref-type="supplementary-material"}W--S4X). Lines, linear fits to individual data. Slope $\left( \varphi \right)$ values ± SEM are shown.(F) Comparison of $\varphi = {\lambda/L}$ from BRE:GFP gradients of wild-type, *Smoc1*^*−/−*^ mutants and *Smoc1*^*−/−*^ mutants injected with *smoc1* mRNA ("rescue").(G--I) Scanning electron micrographs of wild-type (G), *Smoc1* heterozygote control (H), and *Smoc1* homozygote fins (I).(J and K) Average PD (J) and AP (K) fin lengths at 78 hpf in different mutant and morphant (MO) conditions.(L) Comparison of average goodness of fit, $R^{2}$$\left( {\bar{\text{R}}}^{2} \right)$ obtained from collapse analysis (see [Figures S4](#mmc1){ref-type="supplementary-material"}A--S4H) of BRE:GFP gradients in wild-type or *Smoc1*^−/−^ mutants. n represents number of fins analyzed.For all statistical analyses: ^∗∗∗^p \< 0.0001; ^∗∗^p \< 0.01, ^∗^p \< 0.05; two-tailed, unpaired, non-parametric Mann-Whitney tests. Mean ± SEM are shown in all graphs. Anterior, left; distal down. Scale bars, 50 μm. BRE:GFP transgene used: BRE:eGFP ([@bib31]) (B--F, L). See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

The specificity of the scaling phenotype is confirmed by the validated Smoc1 splicing morpholino ([Figures S4](#mmc1){ref-type="supplementary-material"}Q--S4V; [@bib1]). Furthermore, upon expression of *smoc1* by mRNA injection into the CRISPR mutant background, the anterior gradient recovers its scaling, excluding a potential off-target effect ([Figures 5](#fig5){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}; see also theoretical study of this experiment in [Supplemental Methods](#mmc1){ref-type="supplementary-material"}).

Posterior gradient scaling is not affected in the mutant ([Figures 5](#fig5){ref-type="fig"}C, 5E, 5F, [S4](#mmc1){ref-type="supplementary-material"}J, S4M, S4O, and S4X). In addition, we noticed that Smoc1 overexpression through mRNA injection in Smoc1 homozygous embryos led the two gradients to over scale, i.e., the scaling factors $\varphi_{L}$ are larger than in wild type ([Figures 5](#fig5){ref-type="fig"}F, [S5](#mmc1){ref-type="supplementary-material"}A, and S5B). The fact that the mutant interferes only with the anterior gradient but overexpression affects both gradients implies that the function of Smoc1 is redundant for the scaling of the posterior gradient. Indeed, it is possible that a second *smoc* gene (*smoc2*), present in chromosome 13, could play a key redundant role for posterior gradient scaling ([@bib39]).

Interestingly, loss of Smoc1 has consequences on fin growth. [Figures 5](#fig5){ref-type="fig"}G--5K show that growth is impaired in *Smoc1* homozygote mutant and morphant fins ([Figures S4](#mmc1){ref-type="supplementary-material"}Q and S4T). This is consistent with the idea that scaling of the gradient boosts the increase in BMP signaling levels necessary for growth, according to a growth mechanism based on the relative time derivatives of signaling.

Discussion {#sec3}
==========

Gradient Scaling in a Vertebrate Appendage {#sec3.1}
------------------------------------------

In this work, we show the scaling of two BMP signaling gradients ([Figures 3](#fig3){ref-type="fig"}C and 3D) that contribute to growth control of the pectoral fin. A conserved secreted factor, Smoc1, mediates gradient scaling ([Figures 5](#fig5){ref-type="fig"}D and 5F) and itself regulates growth of this organ ([Figures 5](#fig5){ref-type="fig"}G--5K). Furthermore, the amplitude of the gradients display a power-law relationship with the size of the fin ([Figure 3](#fig3){ref-type="fig"}G). Gradient scaling and amplitude power-law are consistent with a process of growth control based on time derivatives of signaling, which can explain our observations where proliferation in the fin is homogeneous ([Figures 2](#fig2){ref-type="fig"}J and 2K). To give stronger support to this model, future experiments imposing different signaling derivatives (for instance, by manipulating BMP levels by heat-shock control at the single-cell level) will address whether this changes the division rate of individual cells in the tissue.

In this report, we have mainly studied the BMP signaling gradients in the proximal-distal axis. [Figures S1](#mmc1){ref-type="supplementary-material"}P--S1S, however, shows that these gradients are also deployed along the anterior-posterior axis, toward the center of the fin. Along the AP axis, the gradients' decay follows an exponential profile and their amplitude also increases over time: the dynamics of the gradients could in principle explain growth control by temporal derivatives of signaling in the entire fin primordium. Further experiments to analyze the gradients along the AP axis might reveal the logic of anisotropic growth in the fin. Indeed, our data show that gradient scaling influences the growth of the fin ([Figures 5](#fig5){ref-type="fig"}G--5K), consistent with such a mechanism based on temporal derivatives ([@bib3], [@bib58], [@bib59]). This mechanism has been seen in insects ([@bib58], [@bib59]) and is seen now in a vertebrate, suggesting that this machinery could be widely employed throughout evolution.

Fin Growth and the Fold Change of Signaling Levels {#sec3.2}
--------------------------------------------------

We have previously shown in a context of scaling and homogeneous growth ([@bib3], [@bib58], [@bib59]) that a power-law relationship for $C_{0}$ with tissue size implies that the proliferation rate $g_{\text{cell}}$ of each cell in the tissue is proportional to the normalized time derivative $\left( {{\overset{˙}{C}}_{\text{cell}}/C_{\text{cell}}} \right)$ of the cellular level of BMP signaling, according to the equation $g_{\text{cell}} \cong \left( {\left( {1 + \varepsilon} \right)/q} \right)\left( {{\overset{˙}{C}}_{\text{cell}}/C_{\text{cell}}} \right)$ (see [Supplemental Methods](#mmc1){ref-type="supplementary-material"} for Theoretical Framework). The time derivative normalized to the actual levels of BMP signaling corresponds to the cellular fold-change of signaling over time. The observed gradient scaling and amplitude power-law imply that cell division occurs when the BMP signaling levels increase by 38% from the beginning of the cell cycle, considering the experimental values we observed for the anisotropy $\varepsilon = 0.65$ and the power-law coefficient $q = 0.92$ (for calculation, see [Supplemental Methods](#mmc1){ref-type="supplementary-material"}).

Taken together, our data suggest a scenario where the fin contains a proximal BMP source that generates a single gradient deployed along the proximo-distal axis, while signaling, as revealed by the BRE reporter, is only seen in the ROI. This is consistent with the presence of BMP signaling antagonists in the endoskeletal disc ([@bib9], [@bib18]), which could decrease the signaling levels in the center of the endoskeletal disc. This could generate an effective scenario where two signaling gradients are deployed in the fin. Importantly, in this setting, the observed fin growth anisotropy ([Figure 2](#fig2){ref-type="fig"}O) and gradient scaling along the *x* axis ([Figures S2](#mmc1){ref-type="supplementary-material"}D, S2E, S2G, and S2H) become compatible with the control of growth by relative increases of BMP signaling levels. Given that Smoc1 mutants affect only scaling of the anterior gradient, a Smoc1 paralog, Smoc2, might cover redundantly its function in the posterior gradient. It is possible that the BMP ligand(s) in the two gradients show different splicing forms, post-translational modifications, or binding partners whether the gene is expressed from the anterior or posterior source. One could speculate that this could allow for a differential mode of action for different Smocs in the anterior versus posterior sides of the fin. Local scaling within a single gradient could allow for local control of patterning and growth, which could give rise to the emergence of complex morphologies.

Computation of Time Derivatives of Signaling {#sec3.3}
--------------------------------------------

Cell-to-cell communication mediated by fold change detection rather than absolute levels of signaling has been described in a number of sensory systems, from chemotaxis in bacteria and amoebas to olfactory or gustatory transduction in *C. elegans* ([@bib2], [@bib7], [@bib8], [@bib16], [@bib17], [@bib32]). In particular, it has been proposed that within the TGFβ superfamily, not only BMP but also TGFβ signaling is mediated by cells measuring the relative increase in signaling over time ([@bib16], [@bib50]). In models where the interactome has been described (yeast and *E. coli*), networks that detect fold change in signaling are vastly over-represented ([@bib5], [@bib33]), suggesting that cells can compute more easily time derivatives than absolute concentration of molecules. In addition, a mechanism mediated by fold change detection and gradient scaling provides solutions supporting homogeneous cell proliferation and organ growth to a finite size ([@bib3]). Further exploration into the specific properties of a fold change detection system during the embryonic growth of the pectoral fin will provide a general framework to understand growth and patterning of vertebrate appendages.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**rabbit anti-BmpR1ba+bGenetexCat\# GTX128200; RRID: [AB_2827925](nif-antibody:AB_2827925){#interref65}rat anti-PhosphoH3 (pSer28)SigmaCat\# H9908; RRID: [AB_260096](nif-antibody:AB_260096){#interref70}mouse anti-Smoc1AbnovaCat\# H00064093-M03; RRID: [AB_530203](nif-antibody:AB_530203){#interref75}rabbit anti-PhosphoSmad 1 (Ser463/465) /5 (Ser463/465) /9 (Ser465/467)Cell SignalingCat\# 13820; RRID: [AB_2493181](nif-antibody:AB_2493181){#interref80}rabbit anti-GFPAbcamCat\# ab290; RRID: [AB_303395](nif-antibody:AB_303395){#interref85}rat anti-GFPSta Cruz BiotechnologyCat\# sc-101536; RRID: [AB_1124404](nif-antibody:AB_1124404){#interref90}rabbit anti-mCherryLiving ColorsCat\# 632496, lot\# 1408015; RRID: [AB_10013483](nif-antibody:AB_10013483){#interref95}rabbit anti-panActinThermofisherCat \#MA5-11869; RRID: [AB_11004139](nif-antibody:AB_11004139){#interref100}**Chemicals, Peptides, and Recombinant Proteins***smoc1* splice blocking morpholinoGene Tools[@bib1]*smoc1* mismatch control morpholinoGene ToolsThis paperDMH1SigmaCAS\# 1206711-16-1MS-222SigmaCAS\# 886-86-2**Deposited Data***smoc1* cDNA sequenceThis studyGenBank: MK285359**Experimental Models: Organisms/Strains**Zebrafish: AB wildtype strainEuropean Zebrafish Resource CenterRRID: ZDB-GENO-960809-7Zebrafish: Tg(EF1α:mAG-zGem(1/100))^rw0410\ h^[@bib52]RRID: ZDB-ALT-101018-2Zebrafish: Tg(Xla.Eef1a1:hist2 h2l-mCherry)[@bib45]RRID: ZDB-FISH-150901-2743Zebrafish: Tg(BmpRE:EGFP)^pt509^[@bib31]RRID: ZDB-ALT-110706-57Zebrafish: Tg(BRE-AAVmlp:eGFP)^mw29^[@bib13]RRID: ZDB-ALT-110308-1Zebrafish: Tg(BRE-AAVmlp:d2EGFP)^mw30^[@bib13]RRID: ZDB-ALT-110310-1Zebrafish: Tg(hsp70l:dnXla.Bmpr1a-GFP)^w30^[@bib44]RRID: ZDB-ALT-050503-2Zebrafish: *Smoc1*^*ug104*^This studyRRID: ZDB-ALT-180625-1**Oligonucleotides**smoc1 cDNA:FWD: 5′-GATCGGCGCGCCCATGAACTGT\
CACAATCTGGC-3′This studyN/Asmoc1 cDNA:\
REV: 5′-CGCTGGCCGCCGACCTTACTG\
AACAAATTTG-3′This studyN/Asmoc1^ug104^ cDNA:FWD: 5′-CAGGCCAAGAAGCGCAG\
GAATCCATTTTC-3′This studyN/Asmoc1^ug104^ cDNA:\
REV: 5′-GAAAATGGATTCCTGCGCTTCTTGGCCTG-3′This studyN/Asmoc1^ug104^ sgRNA:FWD: 5′-TAGGAACAGGCCAAGAA\
GCCGC-3′This studyN/Asmoc1^ug104^ sgRNA:\
REV: 5′-AAACGCGGCTTCTTGGCCTGTT-3′This studyN/ASmoc1^ug104^ genotyping primers:FWD: 5′-CAAGAATCC\
ATTCCCCCC-3′This studyN/ASmoc1^ug104^ genotyping primers:\
REV: 5′-CTTTAGGATTCGTTGATGTCAAAAG-3′This studyN/ASplicing block MO flanking region primers:FWD: 5′-CTTGTTTCAGAGGTCAAAGAGTTG-3′[@bib1]N/ASplicing block MO flanking region primers:\
REV: 5′-GATTAAGCAGCTGGTGTACAAAGAG-3′[@bib1]N/A**Recombinant DNA**pCS2-smoc1 for mRNA and *in situ* probe synthesisThis studyN/ApCS2-smoc1-mCherry for mRNA synthesisThis studyN/ApCS2-smoc1^ug104^-mCherry for mRNA synthesisThis studyN/ApCS2-nls-zCas9-nls for mRNA synthesis[@bib28]N/ApDR274-smoc1sgRNA for CRISPR generationThis studyN/A**Software and Algorithms**MATLAB R2018bMathworks<https://www.mathworks.com/products/matlab.html>Imaris 8.0Bitplane<https://imaris.oxinst.com/packages>Fiji[@bib48]<https://fiji.sc>Prism 7GraphPad<http://www.graphpad.com/scientific-software/prism>Ilastik 1.3.0[@bib23]<https://www.ilastik.org/>Lasergene 15DnaStar<https://www.dnastar.com/software/lasergene/>FinchTVGeospiza<https://www.geospiza.com/finchtv>ExcelMicrosoft<https://products.office.com/en-us/?rtc=1>ZiFiT[@bib47]<http://zifit.partners.org/>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Marcos Gonzalez-Gaitan (<marcos.gonzalez@unige.ch>). Plasmids and zebrafish lines generated in this study are available upon request.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Ethics statement {#sec4.3.1}

This study followed European Union directives (2010/63/EU), the Swiss Animal Protection Act and the Swiss Animal Welfare Ordinance.

### Zebrafish lines and maintenance {#sec4.3.2}

All zebrafish (*Danio rerio*) lines used were maintained in a re-circulating system with a 14 h/day, 10 h/night cycle at 28°C. Crosses were performed with 3- to 12-month old wildtype AB strain adults. Embryos were kept in E3 zebrafish embryo medium at 28.5°C until reaching the desired developmental stage. The transgenic lines used were: Tg(EF1α:mAG-zGem(1/100))^rw0410\ h^ ([@bib52]) (RRID: ZDB-ALT-101018-2); Tg(Xla.Eef1a1:hist2 h2l-mCherry) ([@bib45]) (RRID: ZDB-FISH-150901-2743) -- referred as H2B-mCherry; Tg(BmpRE:EGFP)^pt509^ ([@bib31]) (RRID: ZDB-ALT-110706-57), Tg(BRE-AAVmlp:eGFP)^mw29^ ([@bib13]) (RRID: ZDB-ALT-110308-1) - for simplicity both are denominated BRE:GFP, each figure legend details which transgene was used; Tg(BRE- AAVmlp:d2GFP)^mw30^, referred as BRE:d2GFP ([@bib13]) (RRID: ZDB-ALT-110310-1); Tg(hsp70l:dnXla.Bmpr1a-GFP)^w30^ ([@bib44]) (RRID: ZDB-ALT-050503-2), referred as dnBmpr-GFP.

Method Details {#sec4.4}
--------------

### SPARC related modular calcium binding 1 (Smoc1) sequence and constructs {#sec4.4.1}

The Ensembl sequence for *Danio rerio smoc1* (ENSDARG00000088255) as it appears in the repository misses a signal peptide. NCBI BLAST was performed to identify a predicted signal peptide sequence in the current genome assembly (GRCz11). In addition, an extra exon at the end of the sequence (exon 14) was identified by homology to *Sinocyclocheilus rhinocerous smoc1* sequence (taxID: 307959). This was followed by amplifying the updated *smoc1* cDNA from 5 days post-fertilization (dpf) zebrafish total cDNA together with primers containing AscI and FseI digestion sites at their 5′ and 3′ ends, respectively (FWD: 5′-GATCGGCGCGCCCATGAACTGTCACAATCTGGC-3′; REV: 5′-CGCTGGCCGCCGACC TTACTGAACAAATTTG-3′). The 1530bp amplified fragment was purified using a gel extraction kit (QIAGEN 28706), digested with restriction enzymes AscI and FseI (NEB) and cloned into pCS2+8CmCherry (Addgene \#34935) -- which was previously digested with the same restriction enzymes and treated with Calf intestinal alkaline phosphatase (NEB M0290S). The updated *smoc1* cDNA sequence has been deposited into GenBank: MK285359.

To obtain the construct pCS2-smoc1^ug104^-mCherry, which recapitulates the *Smoc1*^*ug104*^ fish CRISPR mutation, the pCS2-smoc1-mCherry construct was mutated by site directed mutagenesis, using PCR. For this, 600ng of template pCS2-smoc1-mCherry and primers containing the mutation, overlapping the mutation target site were used:

FWD 5′-CAGGCCAAGAAGCGCAGGAATCCATTTTC-3′;

REV 5′-GAAAATGGATTCCTGCGCTTCTTGGCCTG-3′.

Then 1μL of DpnI (NEB) was added directly to the PCR reaction to digest the template DNA at 37°C o/n. This was followed by transformation of competent cells, antibiotic selection, DNA amplification and sequencing for identification of the correct clone.

### *Smoc1*^*ug104*^ CRISPR mutant {#sec4.4.2}

*Smoc1*^*ug104*^ CRISPR mutants (RRID: ZDB-ALT-180625-1), were generated as described ([@bib27]). Briefly, oligos for sgRNA synthesis were designed using ZiFiT software ([@bib47]), (FWD: 5′-TAGGAACAGGCCAAGAAGCCGC-3′; REV: 5′-AAACGCGGCTTCTTGGCCTGTT-3′) annealed and ligated into the pDR274 expression vector (previously digested with BsaI, NEB). Then the sgRNA was synthetized using the Megascript T7 kit following manufacturer's protocol (Ambion). sgRNA purification was performed with the Mega Clear kit (Invitrogen), following its elution procedure. In parallel, Cas9 mRNA was synthetized from pCS2-nls-zCas9-nls plasmid ([@bib28]). One-cell stage wildtype AB embryos were injected with 1nl of a mix containing 300pg Cas9 mRNA and 150pg sgRNA. To test efficiency of sgRNA, injected embryos were genotyped and T7 endonuclease I (NEB) mutation detection assays were performed, as well as sequencing of the region of interest. Founders were identified by genotyping the resulting progeny. From F2 generation onward, *Smoc1*^*ug104*^ mutants were maintained in the BRE:GFP; H2B-mCherry background. For rescue experiments, 20pg of full-length *smoc1* mRNA were injected at one-cell stage into homozygote *Smoc1*^*ug104/ug104*^*;* BRE:GFP; H2B-mCherry embryos and imaged from 48 to 78 hpf. For synthesis details, see below.

### Microinjection of embryos with mRNAs and morpholinos {#sec4.4.3}

One-cell stage wildtype AB or *Smoc1*^*ug104*^*;* BRE:GFP; H2B-mCherry embryos were injected using standard procedures with different *smoc1* mRNA concentrations. This was generated by linearization of *pCS2-smoc1* vector with NotI (NEB), and transcribed using the SP6 mMESSAGE mMACHINE High Yield Capped RNA Transcription Kit (Ambion). The same procedure was performed to obtain *smoc1-mCherry*, *smoc1*^*ug104*^*-mCherry* and Cas9 mRNAs. For antisense morpholino oligonucleotide (MO) injections, 2ng or 12ng of a splicing block MO (5′-CCGGAACTCTGACAGACCTGAGCAA-3′) ([@bib1]) and its respective mismatch control MO (5′-CCGCAAGTCTCACACACCTCAGCAA-3′) were used (Gene Tools, LLC) in BRE:GFP; H2B-mCherry heterozygote embryos. Embryos were left to develop at 28.5°C until the desired stage and then processed for SEM, live imaging or immunostainings. A PV-820 Pico-injector (World Precision Instruments) and a Narashige micromanipulator were used for microinjection.

### Genotyping {#sec4.4.4}

Genomic DNA from embryos or adult caudal fins was extracted using the Kapa Express Extract kit (Kapa Biosystems) according to the manufacturer's protocol. This was followed by performing PCR with KAPA2G Robust HotStart ReadyMix (Kapa Biosystems) with primers surrounding the *smoc1* mutation region (FWD: 5′-CAAGAATCCATTCCCCCC-3′; REV: 5′-CTTTAGGATTCGTTGATGTCAAAAG-3′). Then PCR products were purified using a PCR Purification Kit (QIAGEN) and sent to sequencing. Sequences were analyzed using Finch TV software.

### Embryo heat-shocks {#sec4.4.5}

For heat-shocks, 48 hpf embryos collected from outcrossing heterozygote hsp70:dnBmpr1-GFP with wildtype AB fish were placed into 50ml falcons with pre-heated E3 medium and heat activated in a bath at 38.5°C for 1 h, then transferred to Petri dishes and kept at 28.5°C. GFP positive and negative embryos were selected and fixed for immunostainings 2 h after heat-shock. To assess fin growth upon inhibition of BMP signaling with hsp70:dnBmpr1-GFP, the same procedure as above was performed in intervals of 12 h from 48 until 72 hpf, when embryos were selected and fixed for SEM.

### DMH1 treatment {#sec4.4.6}

For inhibition of BMP signaling with DMH1 ([@bib22]), embryos collected from in-crossing heterozygote BRE:d2GFP; H2B-mCherry transgenic fish were used. At 30 hpf, embryos were selected for both GFP and mCherry signals, dechorionated and placed in 6-well culture dishes (Falcon) containing either DMH1 50μM (Sigma) or DMSO control (Sigma) diluted in E3 embryo medium. Embryos were kept at 28.5°C until 72 hpf, when embryos were live-imaged. Chemical treatments were repeated 3 times with different biological replicates.

### Total RNA isolation and Reverse Transcriptase (RT)-PCR {#sec4.4.7}

Total RNA was extracted from 5 dpf embryos using Trizol reagent (Invitrogen) and treated with DnaseI (Roche) according to the manufacturer's protocol. cDNA was synthesized from 1 μg total RNA using the SuperScript IV First-Strand Synthesis System (ThermoFisher), following the oligo-dT manufacturer protocol.

For morpholino splicing block test ([Figure S3](#mmc1){ref-type="supplementary-material"}L), total RNA extraction and cDNA synthesis from 24 hpf injected embryos was performed as described above. Then a PCR using primers flanking the splicing region (FWD: 5′-CTTGTTTCAGAGGTCAAAGAGTTG-3′, REV: 5′-GATTAAGCAGCTGGTGTACAAAGAG-3′) was performed and visualized by 1% agarose gel electrophoresis.

### Immunofluorescence {#sec4.4.8}

Whole-mount immunostainings were performed as described ([@bib35]). Embryos were mounted in 80% Glycerol, 2% DABCO (Sigma) diluted in PBS and then imaged using a Zeiss LSM780 confocal microscope with a C-Apochromat 40 × water objective or a C-Apochromat 20 × dry objective. The primary antibodies used were: rabbit anti-BmpR1b (BmpR1ba+b 1:200, Genetex); rat anti-PH3 (1:300, Sigma), mouse anti-Smoc1 (1:200, Abnova), rabbit anti-PSmad1/5/9 (1:100, Cell Signaling), rabbit anti-GFP (1:200, Abcam), rat anti-GFP (1:200, Sta Cruz Biotechnology) and rabbit anti-mCherry (1:200, Living Colors \#632496). The secondary antibodies used were: anti-mouse Alexa488, anti-mouse Alexa594, anti-mouse Alexa647, anti-rat Alexa488, anti-rat Alexa594, anti-rabbit Alexa488, anti-rabbit Alexa594 (all 1:500, Molecular probes). Immunostainings were repeated at least 3 times with different biological replicates, per marker and condition.

### *In situ* hybridization {#sec4.4.9}

Whole-mount *in situ* hybridizations in embryos were performed as described ([@bib54]). After histochemical reaction, embryos were fixed in 4% paraformaldehyde, dehydrated progressively into 100% methanol, cleared with benzyl alcohol:benzyl benzoate:xylene mix and mounted in Permount (Fisher, \#10271893)([@bib9]). Images of *in situ* hybridizations were obtained with a Leica M80 stereomicroscope, using a Leica IC80 HD digital camera. Digoxygenin-labeled antisense RNA probe for *smoc1* was synthesized as described ([@bib24]), by linearization of smoc1-pgem-T-easy with AatII (NEB) and transcribed with SP6 polymerase (Promega). *In situs* were repeated 3 times with different biological replicates.

### Western blot {#sec4.4.10}

For protein extracts, 6 hpf wildtype embryos non-injected or injected with either 130pg *smoc1-mCherry*, 130pg *smoc1*^*ug104*^*-mCherry* or 130pg of *smoc1* mRNA were dechorionated by adding 1ml Pronase (10 mg/mL, Sigma) directly to the respective Petri dish, incubating 5 min at RT and followed by washing 3 times with E3. Then 130 embryos of each condition were transferred to 1.5 mL eppendorf tubes and 1 mL of deyolking buffer (55mM NaCl, 1.8mM KCl, 1.25mM NaHCO~3~) was added. This was followed by shaking for 5 min at 1100rpm, centrifugation at 300 g for 1 min and removing the supernatant. Then embryos were washed with wash buffer (110mM NaCl, 3.5mM KCl, 2.7mM CaCl~2~, 10mM TrisHCl pH 8.5) and the centrifugation repeated, leading to a pellet of cells. Cell pellets were subsequently flash frozen in liquid nitrogen and stored at −80°C. Afterward, cell pellets were squashed with a pestle into 100μl of lysis buffer (50mM Tris pH 7.5, 1.5mM MgCl~2~, 125mM NaCl, 0.2% IGEPAL, 5% glycerol and protease inhibitor cocktail -- benzamidine (1mM, Applichem), chymostatine (40μg.ml^−1^, Applichem), antipain (40μg.ml^−1^ Applichem), leupeptine (1μM Applichem), pefabloc (1mM) and PMSF (0.5mM)). The extracts were incubated 40cmin at 4°C with rocking, then cellular debris were cleared by centrifugation at 16000 g for 10cmin at 4°C. The concentration of the extracts was measured using Bradford (Biorad 500-0205) and the extracts were normalized to the least concentrated sample. They were then diluted in LDS sample buffer (Life Technologies) enriched with 2.5% β-mercaptoethanol and analyzed by SDS--PAGE and western blot. In each condition, 20μg of total protein were loaded. SDS--PAGE was performed using NuPAGE 4%--12% Bis-Tris gels (Life Technologies) according to the manufacturer's instructions. Gels were transferred to nitrocellulose membranes using iBLOT (Life Technologies) according to the manufacturer's instructions. For western blot, the antibodies used were: rabbit anti-mCherry (1:1000, Living Colors \#632496), mouse anti-Smoc1 (1:1000, Abnova) and rabbit anti-panActin (1:10000, Thermofisher MA5-11869). Antibodies were diluted in TBS with 0.2% BSA, 1 mM CaCl~2~, 0.02% Thymerosal O/N at 4°C. Western blots were revealed using HRP coupled antibodies (Jackson immunoResearch 1:10000 dilution), Western Bright Quantum (Advansta) chemiluminescence reagents and a Vilber Lourmat Fusion imager. Western blots were repeated 3 times with different biological replicates. For gel source data, see [Data S1](#mmc1){ref-type="supplementary-material"}.

### Scanning electron microscopy (SEM) {#sec4.4.11}

Larvae were fixed o/n at 4°C in 2.5% glutaraldehyde, 4% paraformadehyde, 0.1 M Cacodylate buffer, 2 mM Calcium Chloride. Then larvae were washed in 0.1 M Cacodylate buffer and fixed a second time in 1% OsO~4~ in 0.1 M Cadodylate buffer, for at least 2 h on ice. After this, larvae were washed in H~2~O and subsequently dehydrated to 100% EtOH, in 10% steps. Then larvae were transferred to 100% acetone and kept at 4°C until imaging. Before imaging, larvae went through critical point processing for total dehydration using a Leica EM-CPD030. Then embryos were mounted, gold coated in a JEOL JFC-1200 fine coater and imaged using a JEOL JSM-6510LV. Mounting was performed so that the fin apical surface was parallel to the imaging plane. SEM was repeated at least 3 times with different biological replicates.

### Live imaging {#sec4.4.12}

Confocal live imaging was performed in embryos anaesthetized in 0.1% MS-222 (Sigma) diluted in embryo medium, using a Fluorodish (World Precision Instruments), and an inverted Zeiss LSM780 confocal microscope with a C-Apochromat 40 × water objective.

Light-sheet microscopy was performed using a home-built Selective Plane Illumination Microscopy (SPIM), based on the original design ([@bib26]), with adaptations. A cylindrical lens with a focal length *f = 50* mm (Thor Labs GmbH) was used to generate the light sheet and focused onto the sample using a 10x, NA 0.3 water-immersion objective (UMPLFLN10XW, Olympus). Two lasers were used (λ = 488 nm, Oxxius Laserboxx, and λ = 561 nm, Cobolt Jive) to excite two fluorophores at the same time. An Acousto-Optical Tunable Filter (AOTF, AA OptoElectronic) was used to select the wavelength, intensity and duration of the excitation light. Imaging was done using a 20x, NA 0.5 water-immersion objective (UMPLFLN20XW, Olympus), a *f =* 150 mm 2" achromatic lens (Thor Labs GmbH), a dichroic mirror (t560lpxr, Chroma Technology) to split the fluorescence emission and two cameras (Photometrics CoolSNAP HQ2). Zebrafish larvae were mounted as described ([@bib29]), using a motorized XYZ-rotation stage (Physik Instrumente). Live imaging was repeated at least 5 times with different biological replicates per condition and zebrafish line.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Proliferation {#sec4.5.1}

Quantification of the proliferation patterns and rates were performed using a Fiji ([@bib48]) plugin, ObjectJ ([Figures 2](#fig2){ref-type="fig"}G--2I and 2N). This plugin was used to manually identify all PH3 positive nuclei and to measure the respective fin area, to obtain the mitotic density in the fin. The mitotic density data was fitted to a temporal exponential decay and its goodness of fit $\left( R^{2} \right)$ assessed.

For proliferation density maps ([Figures 2](#fig2){ref-type="fig"}J--2L), we first projected the z stack images of fins expressing zGeminin. We then segmented the zGeminin positive nuclei using Ilastik software ([@bib23]). From each developmental time point, all segmented images were sum-overlaid in Fiji, registering spatially the fins by using their centroid and the PD/AP axes. This way, we record for each pixel the number of fins in which at least one zGeminin positive nuclei is present. We used a lookup table to display the number of overlaid zGeminin positive nuclei per pixel, per n fins. The total number of fins was similar between the different developmental stages considered (n = 8 to 10).

### Fin dimensions and length comparison {#sec4.5.2}

The AP and PD fin lengths were manually measured by drawing a segmented line in SEM images or live imaging images (BRE:GFP; H2B-mCherry transgenics), using Fiji ([Figures 2](#fig2){ref-type="fig"}A--2F and 2M). For the PD axis, the most proximal point was chosen by eye, while the most distal point was defined as the most distant point from the proximal point, at the edge of the fin. The AP axis was defined to be perpendicular to the PD axis, approximately at its midpoint, to capture the widest region of the fin. To measure endoskeletal disc PD or DV length in the SPIM images, the same procedure as above was applied in maximum intensity projections from the H2B-mCherry signal.

Fin length statistical analysis was performed using GraphPad Prism software by carrying out non-parametric, unpaired, two-tailed Mann Whitney t tests between the different conditions. Statistical experimental details can be found in figure legends of [Figures 5](#fig5){ref-type="fig"}J, 5K, [S1](#mmc1){ref-type="supplementary-material"}C, and S1D.

### Anisotropy {#sec4.5.3}

Fin anisotropy $\varepsilon$ ([Figure 2](#fig2){ref-type="fig"}O) was quantified from the PD and AP length values ($L_{PD}$, $L_{AP}$) from the live imaging dataset. Anisotropy is defined as the ratio of the growth rates $g$ along the AP versus PD axis $\varepsilon = \left( {g_{AP}/g_{PD}} \right)$, where $g_{AP} = \left( {{\overset{˙}{L}}_{AP}/L_{AP}} \right)$ with ${\overset{˙}{L}}_{AP}$ the time derivative of the $L_{AP}$ length and $g_{PD} = \left( {{\overset{˙}{L}}_{PD}/L_{PD}} \right)$. Therefore $\left( {{\overset{˙}{L}}_{AP}/L_{AP}} \right) = \varepsilon\ \left( {{\overset{˙}{L}}_{PD}/L_{PD}} \right)$ and taking integrals $log\left( L_{AP} \right) = \varepsilon\ \text{log}\left( L_{PD} \right) + C$, where $C$ is an integration constant. Thus, as in previous reports ([@bib3], [@bib59]), we estimated anisotropy by fitting to the length data the power-law relationship $L_{AP} \sim {L_{PD}}^{\varepsilon}$ and displaying the relationship as a log-log plot where the slope of the line corresponds to the anisotropy.

### BRE:GFP Gradient Quantification {#sec4.5.4}

After image acquisition, we performed 3D rotation, cropping and flattening by using IMARIS software so that the fin endoskeletal disc was aligned along the AP/PD plane. Maximum intensity projections (MIP) were obtained and a region of interest was defined using Fiji ([Figures 1](#fig1){ref-type="fig"}B and 1D). The region of interest (ROI) where the gradient is deployed was defined as an area of 50 pixels width in the endoskeletal disc, along the region abutting the apical fold, which was identified by nuclear density monitored with the H2B-mCherry signal. The BRE:GFP signal intensity in a particular position along the ROI midline corresponds to the average signal in their orthogonal positions within the ROI. The two positions with maximal intensity along the ROI midline were identified as the positions of amplitude $C_{0}$ of the anterior and posterior gradients. No background subtraction was performed in the analysis of BRE:GFP intensity profiles.

In [Figures 1](#fig1){ref-type="fig"}F, 1G, [3](#fig3){ref-type="fig"}A--3D, [5](#fig5){ref-type="fig"}D, 5E, [S4](#mmc1){ref-type="supplementary-material"}K--S4P, S4R--S4S, S4U--S4X, [S5](#mmc1){ref-type="supplementary-material"}A, and S5B the position $s$ in each of the two gradients is defined as the distance to the corresponding peak intensity ($C_{0}$ position) following the path along the ROI midline. Using this coordinate system, system length $L$ was defined as the distance between each peak signal and the ROI midpoint (ROI half-length). Alternatively, in [Figures S2](#mmc1){ref-type="supplementary-material"}D--S2J, the position $x$ corresponds to the distance to the signal peak along the PD axis and the position $y$, to the distance along the AP axis.

In any of these two cases, gradient profiles were fitted to an exponential curve to determine their decay length $\left( \lambda \right)$, goodness of fit $\left( R^{2} \right)$ and confidence values, with custom-made MATLAB code. In order to obtain decay length estimations of good quality, we discarded gradient fits with $R^{2} < 0.8$ (see [Data S2](#mmc1){ref-type="supplementary-material"} for statistical analysis to determine this threshold and full datasets without threshold exclusion). In scaling plots, the selected decay lengths were represented versus fin length and fit to linear regressions. Note that, for this regression, an offset was allowed. In conditions in which there is scaling, the slope (scaling factor,$\ \varphi$) departs significantly from zero and this offset is negligible. For instance, in [Figures 3](#fig3){ref-type="fig"}C and 3D, the offsets were very small (−3.79 ± 4.95 μm and −2.83 ± 5.29 μm for anterior and posterior wild-type gradients, respectively), so we neglected them. In contrast, when scaling fails ([Figures 5](#fig5){ref-type="fig"}C, [S4](#mmc1){ref-type="supplementary-material"}E, and S4G), the slope is closer to zero and the offset is not negligible (26.743 ± 8.82 μm and 19.32 ± 19.18 μm, respectively).

The rationale behind the choice of fitting to a linear regression with or without an offset is as follows. In wild type, the decay length $\lambda$ is proportional to the length of the fin $\ L$. This means that there is no offset: the ratio $\lambda/L$ is constant. If there is an offset, this is not true, but instead ${\left( {\lambda + \text{offset}} \right)/L} = \text{constant}$. When there is "${\lambda/L} = \text{constant}"\ $scaling, then growth control by $\overset{˙}{C}/C$ generates homogeneous growth (see [@bib58]), but not in the other case, when there is an offset. The actual data confirm what is expected: there is no offset in wild type. We allowed an offset when doing the fits in wild type, verifying that these offsets were extremely small (see [Figure S4](#mmc1){ref-type="supplementary-material"}P). When scaling fails (in mutants), there is an "intrinsic length scale," and this intrinsic length of the gradient should not change as the tissue grows. Indeed, in the mutant, there is an offset (the intrinsic decay length of the gradient in the absence of the expander) and this does not change over time, i.e., the slope of the regression is close to zero. This scenario is what we observe experimentally (see [Figure S4](#mmc1){ref-type="supplementary-material"}P). In [Figures 3](#fig3){ref-type="fig"}C, 3D, [5](#fig5){ref-type="fig"}D, 5E, [S4](#mmc1){ref-type="supplementary-material"}K, S4L, S4N, and S4O, data were also averaged within length bins and the SEM is given.

### Phospho-Smad1/5/9 Gradient Quantification {#sec4.5.5}

Quantification of PSmad1/5/9 gradient profiles and scaling plots ([Figures S1](#mmc1){ref-type="supplementary-material"}J--S1L, [S4](#mmc1){ref-type="supplementary-material"}I--S4L, S4N, and S4O) were performed as described for BRE:GFP above. To remove high background levels resulting from the immunostaining, individual z stacks were processed with Fiji plugin Remove Outliers (for bright outliers with radius of 2.0 pixels; threshold 50) and individual intensity profiles were subtracted by the respective minimum intensity value, before fitting to exponential curves to determine their decay length $\left( \lambda \right)$, goodness of fit $\left( R^{2} \right)$ and confidence values.

Quantification of the spatial intensity profile of other markers (H2B-mCherry, Smoc1, Smoc1-mCherry, BmpR1b, BRE:d2GFP) along the ROI midline was performed as described above. Individual profiles were normalized by dividing intensity and length values (entire ROI length) by respective maxima (unless stated in figure legends), followed by interpolation, averaging and plotting mean together with SEM.

### Statistical analysis of $\varphi$ and offsets {#sec4.5.6}

Statistical comparison of gradient scaling factors, $\varphi$ (in [Figure 5](#fig5){ref-type="fig"}F for BRE:GFP gradients, [Figure S4](#mmc1){ref-type="supplementary-material"}M for PSmad1/5/9 gradients) and offsets ([Figure S4](#mmc1){ref-type="supplementary-material"}P) obtained from linear fits of scaling plots, was done using GraphPad Prism software by performing non-parametric, unpaired, two-tailed Mann Whitney t tests between the different conditions. Statistical experimental details can be found in respective figure legends.

### Gradient collapses, density and statistical analysis of ${\bar{\mathbf{R}}}^{2}$ {#sec4.5.7}

To study scaling of the BRE gradients from the raw data without fitting exponentials, we performed analysis of the gradient profiles $C\left( {r,t} \right)$, where $r = {x/L}$ is the relative distance to the $C_{0}$ position. This showed that the relative concentration gradient ${C\left( {r,t} \right)}/{C_{0}\left( t \right)}$ remains unchanged during growth of the fin. The normalized ${C\left( {r,t} \right)}/{C_{0}\left( t \right)}$ profiles "collapse" into a time- and size-independent master curve $\xi\left( r \right) = \left( {{C\left( {r,t} \right)}/{C_{0}\left( t \right)}} \right)$.

For gradient collapses ([Figures S4](#mmc1){ref-type="supplementary-material"}A, S4C, S4E, and S4G), gradient intensity measurements obtained previously were used. Here, full datasets were considered -- without performing exclusions based on goodness of exponential fit$\ \left( R^{2} \right)$. Like before, the maximum intensity peaks of anterior and posterior gradients were identified as well as their respective length. Taking into account that gradients have different lengths, individual normalization by dividing intensity and length values by respective maxima were performed, followed by interpolation and plotting. An average curve and respective standard deviation were then calculated and plotted. To determine the goodness of the collapse, each individual gradient was fit to the average curve (without assuming an exponential profile) and respective $R^{2}$ was calculated. ${\bar{\text{R}}}^{2}\ $corresponds to the average of all obtained $R^{2}$.

Statistical comparison of ${\bar{\text{R}}}^{2}\ $obtained in the different conditions was done using GraphPad Prism software by performing non-parametric, unpaired, two-tailed Mann Whitney t tests between the different conditions. Statistical experimental details can be found in figure legends of [Figure 5](#fig5){ref-type="fig"}L.

Gradient density plots ([Figures S4](#mmc1){ref-type="supplementary-material"}B, S4D, S4F, and S4H) of the obtained collapses were obtained by using a lookup table where each color corresponds to the fraction of normalized gradients passing through a certain bin. Bin size: 0.05 for ordinates and 0.05 for abscissas.

### AP gradients {#sec4.5.8}

A region of interest (AP ROI) was defined using Fiji on the maximum intensity projections (MIP) obtained from BRE:GFP images above. The AP ROI where the anterior-posterior gradient is deployed was defined as an area of 90 pixels height in the endoskeletal disc, covering the two positions with maximal BRE:GFP intensity in the anterior and posterior fin sides ([Figure S1](#mmc1){ref-type="supplementary-material"}P--S1R). From there analysis proceeded as for BRE:GFP gradients above.

### Gradient signaling analysis per cell {#sec4.5.9}

Intensity from BRE:GFP signal in individual cells was performed in straightened posterior gradient ROIs ([Figure S2](#mmc1){ref-type="supplementary-material"}K). From there, proximal (at the source of maximum BRE intensity) and distal (at the end of the visible BRE signal) ROIs were defined. Then, three individual cells per region (per gradient) were outlined in Fiji and intensity measured per cell. To quantify the number of BRE positive cells in gradients ([Figure S2](#mmc1){ref-type="supplementary-material"}L), the same proximal and distal regions were used and ROIs were defined (113px width/height, approximately 20 cells), to allow for nuclei identification (H2B-mCherry signal) and BRE+ counting.

Statistical comparison was done using GraphPad Prism software by performing non-parametric, unpaired, two-tailed Mann Whitney t tests between the different conditions. Statistical experimental details can be found in figure legends.

### Image processing of SPIM movies {#sec4.5.10}

SPIM movies (typically \> 200 Gb) originally stored in MicroManager TIFF-files were converted to ImageJ-TIFF files containing one time point per file. All stacks were cropped in three dimensions to the same size. Registration of time points was done on a 3x downscaled version of the H2B-mCherry dataset to reduce RAM usage and processing time. Nuclei from the H2B-mCherry channel were used as reference points for the Descriptor Based Registration Plugin ([@bib43]), assuming that the average movement of all nuclei between adjacent time points is close to zero. The obtained 3D translation matrix was then applied to the original dataset using MATLAB. The resulting movie was cropped in 3D and the registration procedure was repeated if necessary. The final translation was then applied to the BRE:GFP channel as well. For 3D visualization purposes and $C_{0}$ measurements, image processing ended here.

### Morphogen gradient quantification of SPIM movies {#sec4.5.11}

After image acquisition and processing, the fin PD- and AP-axis were aligned to the *xy* plane, each twentieth time point per movie. For this, three points were manually selected in the pectoral fin: a distal point close to the PD axis, an anterior point close to the AP axis and a posterior point close to the AP axis. Then, an affine transformation matrix to translate/rotate these points into the *xy* plane was calculated and the transformation was performed using the TransformJ affine transform plugin ([@bib37]). After this, a rotation around the z axis was performed to align the PD axis to the y axis. Finally, the image stack was cropped in *z*. To apply these transformations to intermediate time points, linear interpolation was performed to calculate the three points, consequently calculating the respective affine transformation matrix to intermediate time points. Similar interpolation was applied to obtain the rotation around the z axis and the z-crop for intermediate time points. These transformations were then applied on the whole movie using Fiji. At this point, a maximum intensity projection was obtained from the resulting movie. Final registration was done on the MIP of the BRE:GFP channel using the Descriptor Based Registration Plugin ([@bib43]) allowing for Rigid 2D transformations.

To measure BRE:GFP gradients over time, a similar procedure as above for ROI establishment and intensity measurement was performed on the MIP of every fifth image. For the intermediate time points, the spatial coordinates of the line were linearly interpolated and the intensity profile for these time points was measured based on the interpolated line.

Gradient scaling was measured using a model-free intensity-based fitting approach, using MATLAB. Time-adjacent intensity profiles were fit to each other with four fit parameters: Length-scaling factor (S_L, range: 0.8-1.2); Intensity-scaling factor (S_I, range: 0.8-1.2); Length offset (O_L, range: ± 10 μm) to compensate for length differences caused by manually drawing the line; and Intensity offset (O_I, range: 200-500) to include a background signal that does not scale. The value of O_I within this range did not significantly influence the values for S_L, S_I and O_L. To prevent a halt of the fitting optimizer in a local intensity minimum, we used a range (equally spaced points within the range of each fitting parameter) of initial estimates as input to the optimizer and chose the one with the lowest error.

Normalized $C_{0}$ was calculated by taking the cumulative product of BRE:GFP S_L for each time-point (between 45 and 72 hpf), while setting S_L = 1 for T = 0. Ultimately two curves are generated in this way, one in the forward-time direction (fit the curve at T = t+1 to the curve at T = t) and one in the reverse-time direction. The final curve is the average of those two curves.

To determine $q$ ([Figure 3](#fig3){ref-type="fig"}G), the individual normalized $C_{0}$ values were plotted against the respective fin endoskeletal PD length normalized to its length at 45 hpf in log-log scale. Data averaging and respective SEM were then calculated and a power-law fit to the average was performed to determine the slope value $q$.

Measuring $C_{0}$ ([Figures 3](#fig3){ref-type="fig"}E and 3F): For each time point, $C_{0}$ was measured independently from the normalized $C_{0}$ by obtaining the maximum value in a manually selected rectangular/circular region around the location with the highest intensity in the MIP using Fiji ([@bib48]) ([Video S1](#mmc2){ref-type="supplementary-material"}).

Data and Code Availability {#sec4.6}
--------------------------

Source data for [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, and [S1--S5](#mmc1){ref-type="supplementary-material"} are available in the online version of the paper. The accession number for the updated *smoc1* cDNA sequence reported in this paper is GenBank: MK285359. Custom Fiji and MATLAB code to analyze gradients are available upon request.
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